Showing results (101-110 of 313) with videos related to

Sort By:
Pageof 32
Leukemia & Lymphoma|February 28, 2007
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phaseAlfonso Quintás-Cardama, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Cancer|May 19, 2012
Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemiaGautam Borthakur, Hagop Kantarjian, Keyur P Patel, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 2, 2013
Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantationMichael S Mathisen, Hagop Kantarjian, Elias Jabbour, et al.
Haematologica|May 27, 2014
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletionPaolo Strati, Michael J Keating, Susan M O'Brien, et al.
Cancer|June 22, 2010
Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunctionWei-Gang Tong, Hagop Kantarjian, Susan O'Brien, et al.
Current Hematologic Malignancy Reports|December 31, 2010
Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?Deborah A Thomas, Susan O'Brien, Stefan Faderl, et al.
Cancer|September 26, 2003
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phaseHagop Kantarjian, Susan O'Brien, Jorges Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemiaHagop M Kantarjian, Moshe Talpaz, Jorge Cortes, et al.
Cancer|April 4, 2003
Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemiaSherif Ibrahim, Iman Jilani, Susan O'Brien, et al.
Blood|October 24, 2002
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemiaHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Pageof 32